Primary Protection Against Life-Threatening Rabies Infection

Purevax Rabies is primarily used for the active immunisation of healthy cats (12 weeks of age and older). This application is intended to provide protection against the severe symptomatic outcomes associated with the rabies virus. The vaccine is relevant for managing the development of the severe neurological symptoms associated with rabies, which may include aggression, paralysis, and severe functional disruption. This use is commonly part of routine wellness protocols and is applied in contexts where additional symptomatic support is needed. It supports general well-being during symptomatic phases, particularly regarding the risks of a condition marked by increased physiological stress and severe functional disruption.

Benefit of a Non-Adjuvanted Formulation in Feline Patients

This preparation provides a formulation benefit by being a non-adjuvanted vaccine. This characteristic is relevant for easing symptoms related to inflammatory or irritative states. This approach is applied across domains where additional symptomatic support is needed, which may be part of symptomatic management within feline veterinary protocols. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Protection Against Severe Neurological Symptoms

The primary use is applied in addressing severe neurological symptoms related to the rabies virus, contributing to the cat's health maintenance and supporting public health protocols.

Regulatory References

1. European Medicines Agency (EMA) product information

The official eligibility for Purevax Rabies, a veterinary vaccine, is defined by strict regulatory conditions regarding the recipient species, age, and health status. The product is exclusively indicated for the feline species (cats). It is authorized for use in kittens and cats 12 weeks of age and older, establishing the minimum threshold for initial administration.

Regulatory documentation states that there are no absolute contraindications listed, meaning no specific pre-existing condition formally prohibits its use in an otherwise healthy, age-appropriate cat.

However, use is conditional on the animal's current health. A primary restriction in the labeling specifies that the vaccine must only be administered to healthy animals. This officially excludes any cat presenting as clinically unwell or unhealthy. Furthermore, the safety of Purevax Rabies has not been established for administration during pregnancy or lactation. This means use during these reproductive phases is not documented as safe under the official regulatory labeling, defining a population for restricted use.

Interactions with other medicines and products

Official regulatory documents describe specific constraints regarding the co-administration of Purevax Rabies with other medicinal products, primarily focusing on maintaining the vaccine's intended efficacy.

Documented Interaction Rules

The most stringent requirement is a procedural restriction against combining the vaccine: Purevax Rabies must not be mixed with any other veterinary medicinal product nor administered concomitantly (at the same time) with any other medicinal product.

Product Category	Interaction Implication	Constraint Type
Immunosuppressive Agents (e.g., corticosteroids)	Compromised immune response	Condition-specific restriction
Other Vaccines (non-rabies)	Potential interference	Timing-based interval

Constraints on Use

Timing-based constraints are defined for use with other vaccines. An interval of 14 days should be respected between the administration of Purevax Rabies and the administration of other non-rabies vaccines. This measure is intended to minimize potential interference and ensure the optimal development of the immune response.

Condition-specific constraints apply to animals that are currently undergoing treatment with immunosuppressive agents. The official documentation states that the vaccine should not be used in this population because the desired protective immune response may not be fully attained. These requirements are established in regulatory documentation to manage the risk of reduced immunogenicity when the product is used alongside substances known to affect the immune system.

Inducing Antigen Expression and Presentation

This domain covers how the vaccine-derived genetic material is introduced into host cells, leading to the expression of key target proteins. This process initiates early molecular steps in the host's immune system, primarily involving antigen-presenting cells that capture and display the protein fragments to activate subsequent immunological pathways.

---

Modulating the Adaptive Immune Cascade

This mechanistic domain describes the targeted activation of the adaptive immune system, affecting systems where T-lymphocytes and B-lymphocytes dominate the immune reaction. The mechanism engages molecular signaling sequences that regulate the differentiation and proliferation of these cells, leading to the production of highly specific mediators, including specialized antibodies and effector T-cells.

---

Establishing Immunological Memory and Response

This cluster focuses on the downstream physiological consequence of the initial activation, resulting in the establishment of a sustained cellular and humoral response. The mechanism describes the formation of long-lived memory cells, aiding in the maintenance of T- and B-cell populations and facilitating secondary cascade initiation upon re-exposure to the specific antigen.

Purevax Rabies is a veterinary medicinal product intended for the active immunisation of healthy cats against mortality due to rabies infection. It is a suspension for injection administered via the subcutaneous route.

Dosage and Administration

The vaccine is administered as a single 1 mL dose. For the primary vaccination course, one injection is given from 12 weeks of age.

Vaccination Step	Administration	Timing
Primary Vaccination	Single 1 mL dose	From 12 weeks of age
Revaccination	Single 1 mL dose	1 year after primary vaccination
Subsequent Revaccination	Single 1 mL dose	At intervals of up to 3 years

Handling and Storage

Purevax Rabies must be handled using usual aseptic procedures. The reconstituted product should be a light pink to pale yellow, homogenous suspension. It is important to use the vaccine immediately after it has been reconstituted or the container has been first opened. The product must be stored refrigerated between 2 C and 8 C (35.6 F and 46.4 F) and should not be frozen. It is generally recommended to avoid vaccination of pregnant cats, as safety has not been established during pregnancy and lactation. This vaccine is for animal use only and is restricted to use by or under the direction of a veterinarian.

Research evidence / Overview of Studies for Purevax Rabies

Evidence for Use in Active Immunisation Against Rabies Infection

The core evidence for this preparation focuses on studies that examined its ability to establish an immune response against the rabies virus. The research examined this by conducting controlled challenge studies, which are standard procedures in vaccine development. These studies explored their effect on outcomes related to clinical protection and survival in healthy cats following subsequent exposure to the virulent virus.

The findings from these controlled studies indicate that vaccinated animals, under the specific research conditions, showed patterns related to survival and the establishment of active immunity. This research provides context for the specific use of the product. The evidence primarily derives from controlled laboratory challenge tests, and these results apply only to the populations studied under strict research conditions. There is limited information for how these findings relate to long-term outcomes under natural exposure settings in the field.

---

Research on Antibody Levels and Onset of Immunity

Studies were evaluated in healthy cats to measure specific markers of immune activation, such as the seroconversion rate and the Rabies Virus Neutralizing Antibody (RVNA) Titer. The research describes that the onset of immunity—the time it takes for adequate antibody levels to develop—was measured across defined time intervals. Studies reported that the majority of the observed populations showed patterns related to achieving the antibody threshold consistent with research used for protection. Follow-up durations for measuring the initial onset of immunity were limited to short-term observation periods.

---

Studies on the Duration of Immunity and Long-Term Follow-up

To understand how long the vaccine's effect persists, studies were observed in cats over intermediate and long-term follow-up durations. Researchers monitored the persistence of the RVNA Titer to understand the persistence of antibody levels. This research examined whether the antibody levels consistent with research thresholds were maintained over a one-year and, in some protocols, a three-year period following the initial vaccination series. The data describes patterns related to the maintenance of the immune marker that regulators rely on to describe the observed persistence of the immune marker. Long-term effects beyond the defined re-vaccination intervals are not fully established.

---

What is Still Uncertain in the Research Record

The research record highlights several areas where certainty remains low. The primary limitation is that most evidence was derived from highly controlled, small-scale laboratory challenge tests, meaning the results apply only to the populations studied under those specific conditions. Evidence quality may vary across studies, and comparative evidence against a range of alternative rabies vaccines remains limited. Furthermore, the safety and immunological response was not established in studies involving animals that are pregnant or lactating.

Key Studies & References

1. PUREVAX RABIES - European Commission, Community Register of veterinary medicinal products
2. Rabies Virus Neutralizing Antibody Levels in Veterinary Medical Professionals: A Cross Sectional Study from Samples Collected at U.S. Veterinary Continuing Education Conferences (Discusses $0.5, mathrm{IU/mL}$ threshold)
3. Rabies vaccination and level of protection (Discusses $0.5, mathrm{IU/mL}$ threshold and RFFIT/FAVN test)

Common questions about Purevax Rabies (FAQ)

---

Q: How long does the immunity last after my cat receives the Purevax Rabies vaccine?

Official product information provides the duration of the established immune response, which guides the timing for revaccination. The initial duration of immunity following the primary vaccination course is documented to be 1 year. Following the first revaccination dose, the duration of immunity is documented to support revaccination at 3-year intervals.

---

Q: What should I do to safely dispose of any unused Purevax Rabies vaccine?

Regulatory information specifies that any unused vaccine or waste material must be safely inactivated prior to disposal. Methods of inactivation described in the regulatory documents include boiling, incineration, or the use of an appropriate disinfectant. All final disposal must occur in accordance with local requirements for pharmaceutical waste.

---

Q: How soon after the shot will my cat be protected from the rabies virus?

According to the official product information, the onset of immunity—the time it takes for adequate protective levels to develop—is established 4 weeks after the primary vaccination course. This time frame marks the onset of immunity, which means the cat is considered to have developed adequate antibody levels consistent with the product's research.

How to Store and Dispose of Purevax Rabies

Official Storage Conditions

The product must be refrigerated at a temperature range between 2 C and 8 C and must be protected from light. It is mandatory to store in the original container and do not freeze the vaccine. The unopened product has a shelf life of 18 months. Once the packaging has been opened (broached), the contents must be used immediately.

Handling and Disposal

The product must be kept out of the sight and reach of children. Unused vaccine or waste material must be inactivated before disposal. Inactivation can be achieved through methods such as boiling, incineration, or immersion in an appropriate disinfectant. All final disposal must occur in accordance with local requirements for pharmaceutical waste.